CD38TIFN-γCD38

Mariam Murtadha1,2, Miso Park3, Yinghui Zhu1,2,4

  • 1Department of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA.

Blood
|February 23, 2024
PubMed
概括

一种针对CD38+急性髓性白血病 (AML) 细胞的新疗法通过吸引T细胞和诱导干扰素玛 (IFN-γ) 有效地消除白血病干细胞 (LSC). 这种方法增强了对抗性LSCs的CD38表达,导致它们在不损害健康细胞的情况下被破坏.